Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Immunol.

Sec. Multiple Sclerosis and Neuroimmunology

Diagnostic Biomarkers for Differentiating AQP4-IgG-Negative NMOSD from Other Nervous System Autoimmune Disorders: A Retrospective Study

Provisionally accepted
Wencan  JiangWencan Jiang1Yang  JiaoYang Jiao1Menglue  ZhangMenglue Zhang1Chenxu  WangChenxu Wang1Xiaotong  LiXiaotong Li1Kelin  ChenKelin Chen1Yaowei  DingYaowei Ding1Haoran  LiHaoran Li1Lijuan  WangLijuan Wang1Siwen  LiSiwen Li1Ziwei  LiuZiwei Liu1Chi  HuangChi Huang2Lei  LiuLei Liu2*Guojun  ZhangGuojun Zhang1*
  • 1Beijing Tiantan Hospital, Capital Medical University, Beijing, China
  • 2Capital Medical University, Beijing, China

The final, formatted version of the article will be published soon.

Background and Objective: The clinical manifestations of neuromyelitis optica spectrum disorders (NMOSD) overlap with those of other central nervous system (CNS) disorders, making differential diagnosis based on symptoms alone difficult. This study aimed to identify distinguishing indicators of aquaporin-4 (AQP4) IgG-negative NMOSD and assess their diagnostic value. Methods: We analyzed four groups: 85 patients with AQP4-IgG-negative NMOSD, 192 with AQP4-IgG-positive NMOSD, 547 with other nervous system autoimmune disorders (e.g., multiple sclerosis, Guillain-Barré syndrome, and viral and autoimmune encephalitis), and 269 healthy controls matched for sex, age, and BMI.A diagnostic model was established using clinical, biochemical, and cerebrospinal fluid (CSF) variables. The dataset was divided into training and internal validation cohorts, and model performance was further assessed through external validation using an independently collected dataset obtained during the same study period. Results: We enrolled 1,093 participants. The AQP4-IgG-negative NMOSD group showed: higher diplopia incidence (35.29% vs. 17.19% in positive NMOSD, 17.18% in controls; P<0.001); lower limb sensory abnormalities (76.47% vs. 89.58%, P=0.0056) and urinary dysfunction (36.47% vs. 57.29%, P=0.0017) than positive cases; predominant brainstem involvement (50.59% vs. 31.77% in positive, 28.70% in controls; P<0.001); moderate spinal cord involvement (70.59% vs. 88.02% in positive, 38.57% in controls; P<0.001); and altered thyroxine, apolipoprotein A1, eosinophils , and basophils. After false discovery rate correction (q<0.1), diplopia, brainstem involvement, spinal cord involvement, serum albumin, and CSF albumin remained significant. A combined model incorporating twelve predictors (Ocular symptoms, Gastrointestinal symptoms, Water swallowing and choking difficulties, Cerebral lobes, Centrum semiovale, Brainstem1, Cerebral ganglia, Spinal cord, APOA1, Ca, Toxoplasma gondii IgM Antibody, CSF IgG) achieved an AUC of 0.936in the training cohort and 0.929 in external validation. Discussion: AQP4-IgG-negative NMOSD shows distinct clinical, imaging, and laboratory profiles compared to other nervous system autoimmune disorders. A multi-indicator diagnostic approach offers higher accuracy than single-marker diagnostics.

Keywords: AQP4-IgG, Clinical Characteristics, Laboratory examinations, Magnetic Resonance Imaging, Neuromyelitis optica spectrum disorder

Received: 29 May 2025; Accepted: 19 Dec 2025.

Copyright: © 2025 Jiang, Jiao, Zhang, Wang, Li, Chen, Ding, Li, Wang, Li, Liu, Huang, Liu and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Lei Liu
Guojun Zhang

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.